^
Association details:
Biomarker:RET positive + KRAS G12V
Cancer:Non Small Cell Lung Cancer
Drug Class:RET inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

1007P - Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC

Published date:
09/05/2022
Excerpt:
This multicentric retrospective study included 24 centres. Eligible pts had a RET+ aNSCLC, were treated with a RETi….KRAS G12V mutation and SMARCA4 alterations were found only in poor responders (4.5% vs 0%, p=0.2; and 25% vs 0%, p=0.04, respectively)….SMARCA4 and KRAS co-mutations may have a role in primary resistance to RETi.